ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.
ETFOptimize | HOME
Close Window
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Market News Alert: DarioHealth Beats Q4 Expectations, Reports 398% Growth in B2B Recurring Revenue

By: via Business Wire

Digital health leader DarioHealth outperforms forecast with multi-condition platform, 90%+ client retention, 5x ROI for payers, expands Medicare/Medicaid partnerships, accelerates path to profitability with 83 client base, GLP-1 integrations, and surging healthcare adoption

Market News Alerts Updates: Market News Alerts Reports: DarioHealth Corp. (Nasdaq: DRIO) reported fourth quarter revenue of $7.6 million, beating analyst consensus of $7.39 million. B2B2C recurring revenue surged 398% year-over-year to $5.6 million in Q4, driven by rapid employer and health plan adoption of the company's comprehensive chronic care platform. Gross margins in the B2B2C business exceeded 80% over the past three quarters.

Full-year 2024 revenue reached $27.0 million, up 32.9% from 2023, while Q4 operating loss decreased by 35% compared to Q1 2024. The company secured 36 new clients in 2024, bringing its total client base to 83 organizations with an impressive client renewal rate above 90%. Dario's solutions have demonstrated significant clinical outcomes, including a 5x ROI for payers and reducing A1C levels for diabetes patients by 2.3 points.

"Our strategic initiatives yielded remarkable financial improvements throughout 2024 in both our top and bottom line. We are already seeing this positive trajectory continue into 2025," stated CEO Erez Raphael. The company's $34.5 million cash position is expected to fund operations through to operational cash flow breakeven by the end of 2025, with an additional 20% reduction in operating expenses anticipated by Q4 2025.

Recent strategic expansions, including a Blue Cross Blue Shield agreement and integration with GLP-1 weight management programs, position Dario to continue its rapid growth trajectory in the expanding digital health market.

During the company’s earnings call, CEO Erez Raphael noted: “It's clear that 2024 was transformational year for DarioHealth. We are entering 2025 with strong momentum and solid financial foundation and a clear strategic vision that sets us apart in the healthcare technology space.”

Recent News from Dario:

* Disclaimer: Nothing in this report constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This report is published by Market News Alerts, a brand which is part of the Wall Street Wire™ network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This report contains paid promotional content related to DarioHealth and was produced as part of their paid subscription to Wall Street Wire. This report has not been reviewed or approved by DarioHealth prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 
IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.